NO983001L - Vitronectin-reseptor-antagonister - Google Patents
Vitronectin-reseptor-antagonisterInfo
- Publication number
- NO983001L NO983001L NO983001A NO983001A NO983001L NO 983001 L NO983001 L NO 983001L NO 983001 A NO983001 A NO 983001A NO 983001 A NO983001 A NO 983001A NO 983001 L NO983001 L NO 983001L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- het
- cycloalkyl
- receptor antagonists
- vitronectin receptor
- Prior art date
Links
- 102100022337 Integrin alpha-V Human genes 0.000 title abstract 2
- 108010048673 Vitronectin Receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 229940122331 Fibrinogen antagonist Drugs 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US936795P | 1995-12-29 | 1995-12-29 | |
| PCT/US1996/020327 WO1997024124A1 (en) | 1995-12-29 | 1996-12-20 | Vitronectin receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO983001D0 NO983001D0 (no) | 1998-06-26 |
| NO983001L true NO983001L (no) | 1998-08-26 |
Family
ID=21737218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO983001A NO983001L (no) | 1995-12-29 | 1998-06-26 | Vitronectin-reseptor-antagonister |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6159964A (enExample) |
| EP (1) | EP0906103A1 (enExample) |
| JP (1) | JP2000502704A (enExample) |
| KR (1) | KR19990076877A (enExample) |
| CN (1) | CN1209063A (enExample) |
| AU (1) | AU1295597A (enExample) |
| BR (1) | BR9612381A (enExample) |
| CZ (1) | CZ203898A3 (enExample) |
| IL (1) | IL125030A0 (enExample) |
| NO (1) | NO983001L (enExample) |
| PL (1) | PL327626A1 (enExample) |
| TR (1) | TR199801254T2 (enExample) |
| WO (1) | WO1997024124A1 (enExample) |
| ZA (1) | ZA9610854B (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10504825A (ja) * | 1994-08-22 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | 二環式化合物 |
| TR199801255T2 (xx) * | 1995-12-29 | 1998-10-21 | Smithkline Beecham Corporation | Vitronektin resept�r antagonistleri. |
| ES2185009T3 (es) * | 1996-04-10 | 2003-04-16 | Merck & Co Inc | Antagonistas de alfa y beta 3'. |
| US20030125317A1 (en) | 1996-10-02 | 2003-07-03 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| DE19653645A1 (de) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
| US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
| DE19653647A1 (de) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| CO4920232A1 (es) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
| US6239138B1 (en) * | 1997-07-25 | 2001-05-29 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
| EP1047425A4 (en) * | 1997-12-17 | 2009-04-22 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
| JP2002504534A (ja) | 1998-02-26 | 2002-02-12 | セルテック・セラピューティクス・リミテッド | α４インテグリンの阻害剤としてのフェニルアラニン誘導体 |
| IL138245A0 (en) * | 1998-03-10 | 2001-10-31 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| SE9803773D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Pharma Prod | Compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1150965A4 (en) | 1999-02-03 | 2002-05-15 | Merck & Co Inc | BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS |
| CA2371824A1 (en) * | 1999-02-20 | 2000-08-24 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | .beta.-alanine derivatives |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| EP1198231A1 (en) | 1999-07-21 | 2002-04-24 | American Home Products Corporation | Bicyclic antagonists selective for the(alpha)v(beta)3 integrin |
| DE19939980A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
| US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
| GB9929988D0 (en) * | 1999-12-17 | 2000-02-09 | Celltech Therapeutics Ltd | Chemical compounds |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| DE60130910T2 (de) | 2000-04-17 | 2008-07-10 | Ucb Pharma, S.A. | Enamin-derivate als zell-adhäsionsmoleküle |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| DE10028402A1 (de) * | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
| WO2002004426A1 (en) | 2000-07-07 | 2002-01-17 | Celltech R & D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
| CA2417059A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
| JP2004521079A (ja) * | 2000-08-29 | 2004-07-15 | ファルマシア・コーポレーション | アルファーｖベータ３アンタゴニストとして有用な二環式環系を含有する化合物 |
| BR0113671A (pt) * | 2000-08-30 | 2004-01-06 | Pharmacia Corp | Antagonistas de integrina alfa v beta 3 gem-substituìda |
| US6531494B1 (en) * | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6472372B1 (en) | 2000-12-06 | 2002-10-29 | Ortho-Mcneil Pharmaceuticals, Inc. | 6-O-Carbamoyl ketolide antibacterials |
| KR100376088B1 (ko) * | 2001-03-09 | 2003-03-28 | 주식회사 태평양 | 3-아미노프로필코질포스페이트 및 그의 염을 함유한미백화장료 조성물 |
| CN1247258C (zh) | 2001-04-24 | 2006-03-29 | 默克专利有限公司 | 使用抗血管生成剂和TNFα的联合疗法 |
| KR20040058229A (ko) | 2001-10-22 | 2004-07-03 | 더 스크립스 리서치 인스티튜트 | 항체 표적화 화합물 |
| CA2469304A1 (en) | 2001-12-05 | 2003-06-19 | Ortho-Mcneil Pharmaceutical, Inc. | 6-o acyl ketolide antibacterials |
| GB0130341D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| US20070141666A1 (en) | 2003-09-26 | 2007-06-21 | Applied Research Systems Ars Holding N.V. | Leader sequences for use in production of proteins |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| WO2007048127A2 (en) * | 2005-10-20 | 2007-04-26 | The Scripps Research Institute | Fc labeling for immunostaining and immunotargeting |
| AU2006332694A1 (en) * | 2005-12-30 | 2007-07-12 | Alantos Pharmaceuticals, Holding, Inc. | Substituted bis-amide metalloprotease inhibitors |
| KR20080089489A (ko) | 2006-01-18 | 2008-10-06 | 메르크 파텐트 게엠베하 | 인테그린 리간드를 사용하는 암치료용 특이적 요법 |
| EA017864B1 (ru) | 2007-01-18 | 2013-03-29 | Мерк Патент Гмбх | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака |
| DE102007038250A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
| EP2730282A1 (en) | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| CN101945853B (zh) | 2007-12-21 | 2014-08-20 | 配体药物公司 | 选择性雄激素受体调节剂(sarm)及其应用 |
| JP2012517447A (ja) | 2009-02-10 | 2012-08-02 | ザ スクリプス リサーチ インスティチュート | 化学的にプログラムされたワクチン接種法 |
| WO2010135524A1 (en) | 2009-05-22 | 2010-11-25 | Exelixis, Inc. | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
| AU2010252280A1 (en) | 2009-05-25 | 2012-01-19 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| ES2864079T3 (es) | 2014-05-30 | 2021-10-13 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos |
| BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
| SG11201809559UA (en) | 2016-06-13 | 2018-12-28 | Glaxosmithkline Ip Dev Ltd | Substituted pyridines as inhibitors of dnmt1 |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| CN108558836A (zh) * | 2018-05-14 | 2018-09-21 | 东南大学 | 一类具有双重作用机制的dpp-4抑制剂及其用途 |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| PT3844162T (pt) | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| AU2020257397B2 (en) | 2019-04-19 | 2026-02-26 | Ligand Pharmaceuticals Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3450707A (en) * | 1966-12-13 | 1969-06-17 | Sterling Drug Inc | Certain 2-anilino-pyridine derivatives |
| US3627754A (en) * | 1970-05-13 | 1971-12-14 | Hoffmann La Roche | Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts |
| ATE236882T1 (de) * | 1992-12-21 | 2003-04-15 | Smithkline Beecham Corp | Bicyklische fibrinogen antagoniste |
| ZA955391B (en) * | 1994-06-29 | 1996-02-09 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| ZA9610853B (en) * | 1995-12-29 | 1998-04-06 | Smithkline Beecham Corp | Processes and intermediates for preparing pharmaceuticals. |
-
1996
- 1996-12-20 WO PCT/US1996/020327 patent/WO1997024124A1/en not_active Ceased
- 1996-12-20 JP JP9524453A patent/JP2000502704A/ja active Pending
- 1996-12-20 AU AU12955/97A patent/AU1295597A/en not_active Abandoned
- 1996-12-20 US US09/091,937 patent/US6159964A/en not_active Expired - Fee Related
- 1996-12-20 PL PL96327626A patent/PL327626A1/xx unknown
- 1996-12-20 KR KR1019980705004A patent/KR19990076877A/ko not_active Withdrawn
- 1996-12-20 IL IL12503096A patent/IL125030A0/xx unknown
- 1996-12-20 BR BR9612381A patent/BR9612381A/pt unknown
- 1996-12-20 TR TR1998/01254T patent/TR199801254T2/xx unknown
- 1996-12-20 CN CN96180114A patent/CN1209063A/zh active Pending
- 1996-12-20 CZ CZ982038A patent/CZ203898A3/cs unknown
- 1996-12-20 EP EP96943818A patent/EP0906103A1/en not_active Withdrawn
- 1996-12-23 ZA ZA9610854A patent/ZA9610854B/xx unknown
-
1998
- 1998-06-26 NO NO983001A patent/NO983001L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000502704A (ja) | 2000-03-07 |
| NO983001D0 (no) | 1998-06-26 |
| IL125030A0 (en) | 1999-01-26 |
| AU1295597A (en) | 1997-07-28 |
| BR9612381A (pt) | 1999-07-13 |
| CZ203898A3 (cs) | 1999-03-17 |
| PL327626A1 (en) | 1998-12-21 |
| TR199801254T2 (xx) | 1998-10-21 |
| ZA9610854B (en) | 1998-04-02 |
| US6159964A (en) | 2000-12-12 |
| EP0906103A4 (enExample) | 1999-04-07 |
| WO1997024124A1 (en) | 1997-07-10 |
| KR19990076877A (ko) | 1999-10-25 |
| CN1209063A (zh) | 1999-02-24 |
| EP0906103A1 (en) | 1999-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9605442A (es) | Nuevos usos para antagonistas del factor de liberacion de corticotropina. | |
| NO940874L (no) | 5-HT4 reseptor-antagonister | |
| ATE290015T1 (de) | Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen | |
| LU91433I2 (fr) | "Tenofovir disoproxil et les sels, en particulier le fumarate, hydrates, tautomers et solvates en combination avec l'emtricitabine et l'efavirenz (ATRIPLA) | |
| TR200102042T2 (tr) | Spiro fropiridinlerin, tedavide faydalı yeni aralkil aminleri. | |
| MY105527A (en) | Pyrrolidine derivatives. | |
| MXPA05010760A (es) | Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda). | |
| EA199900756A1 (ru) | Замещенные изохинолины в качестве нервно-мышечных блокаторов ультракраткосрочного действия | |
| GR3021874T3 (en) | Improvements in or relating to excitatory amino acid receptor antagonists | |
| HU9601634D0 (en) | Morpholine and thiomorpholine tachykinin receptor antagonists | |
| ZW1387A1 (en) | New dihydrobenzofuran-and chroman-carboxamide derivatives,processes for the preparation thereof and use thereof as neuroleptics | |
| AR007352A1 (es) | Derivados sustituidos de bencimidazol, proceso para su preparacion, formulacion farmaceutica que los contiene, y uso de dichos derivados para la manufactura de medicamentos | |
| NO20001515L (no) | Vitronektin reseptor-antagonist | |
| GEP20094697B (en) | Condensed purine derivatives as a1 adenosine receptor antagonists | |
| TW360652B (en) | Acryloyl substituted disstamycin derivatives, process for preparing them, and pharmaceutical composition comprising them | |
| CA2207348A1 (en) | Benzimidazole derivatives | |
| DK0573218T3 (da) | 4-carboxyimidazolderivater som angiotensin-II antagonister og deres terapeutiske anvendelse | |
| NO973652D0 (no) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist | |
| EP1228758A4 (en) | PROHYLACTIC AND THERAPEUTIC AGENTS FOR INFLAMMABLE COLON DISEASES | |
| NO975660L (no) | Anvendelse av benzimidazoler for fremstilling av et medikament for behandling av leukemi | |
| WO1995001170A3 (en) | Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders | |
| NO945079L (no) | Syklopentadienylmagnesium-broforbindelser, fremgangsmåte for deres fremstilling, og deres anvendelse for fremstilling av metallocener | |
| YU6396A (sh) | Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija | |
| DK0896822T3 (da) | 4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister | |
| NZ533358A (en) | 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |